Healios K.K.
TSE:4593 Stok Raporu
Healios K.K Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6 Healios K.K şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler Toplam Hissedar Getirisi -28.3% Gelecekteki Temettü Verimi 0% Temettü Büyümesi n/a Bir sonraki temettü ödeme tarihi n/a Eski temettü tarihi n/a Hisse başına temettü n/a Ödeme oranı n/a
Son temettü ve geri alım güncellemeleri
Tüm güncellemeleri göster
Healios K.K. Announces Agreement with the FDA on Pivotal, Global Phase 3 "REVIVE-ARDS" Clinical Trial Sep 11
Price target increased by 17% to JP¥340 Sep 09
Healios K.K. to Report Q3, 2024 Results on Nov 13, 2024 Aug 27
Consensus EPS estimates upgraded to JP¥29.83 loss Jun 29
Healios K.K. to Report Q2, 2024 Results on Aug 13, 2024 Jun 06
Is Healios K.K (TSE:4593) Using Too Much Debt? May 31
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 16
New major risk - Share price stability Apr 09 Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC . Apr 05
Healios K.K. to Report Q1, 2024 Results on May 13, 2024 Mar 23
Consensus revenue estimates increase by 64% Mar 09
Consensus revenue estimates fall by 24% Feb 22
Consensus revenue estimates fall by 24% Feb 21
Consensus revenue estimates fall by 24% Feb 21
Consensus revenue estimates fall by 24% Feb 21
Consensus revenue estimates fall by 24% Feb 21
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 17
Healios K.K., Annual General Meeting, Mar 27, 2024 Feb 16
Healios K.K. and Procellcure Inc. Announce Start of Ards Clinical Trial in Japan Feb 03 Healios K.K. announced that it expects to receive ¥2.2600715 billion in funding Jan 26
Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan Jan 19
Consensus EPS estimates upgraded to JP¥56.76 loss Dec 23
Healios K.K. to Report Fiscal Year 2023 Results on Feb 14, 2024 Dec 05
Third quarter 2023 earnings released: JP¥9.98 loss per share (vs JP¥12.31 loss in 3Q 2022) Nov 17
Consensus revenue estimates increase by 130% Oct 12
New minor risk - Market cap size Oct 11
HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051 Oct 11
Healios K.K. to Report Q3, 2023 Results on Nov 14, 2023 Sep 24
HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia Sep 16
Price target increased by 11% to JP¥845 Aug 30
Second quarter 2023 earnings released: JP¥10.37 loss per share (vs JP¥32.62 loss in 2Q 2022) Aug 16
Healios K.K. Announces Use of 3D Bioreactor-Based Manufacturing Method Produced Product for ARDS Jul 06
HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011) Jun 23
Healios K.K. to Report Q2, 2023 Results on Aug 14, 2023 Jun 11
Healios K.K. Announces Submission of Clinical Trial Notification for RPE Tail Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011) May 25
First quarter 2023 earnings released: JP¥11.52 loss per share (vs JP¥26.47 loss in 1Q 2022) May 17
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 01
Consensus EPS estimates upgraded to JP¥60.13 loss Mar 04
Price target decreased by 19% to JP¥762 Mar 03
Forecast to breakeven in 2025 Feb 18
Forecast to breakeven in 2025 Feb 15
Healios K.K. Announces Management Changes Jan 17
Forecast to breakeven in 2025 Jan 14
High number of new directors Dec 31
Healios K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023 Dec 06
Third quarter 2022 earnings released: JP¥12.31 loss per share (vs JP¥34.86 loss in 3Q 2021) Nov 16 Healios K.K. announced that it has received ¥100.0316 million in funding from SATAKE Corporation Nov 08
HEALIOS Announces Results from the TREASURE Study Nov 03 Healios K.K. announced that it expects to receive ¥100.0316 million in funding from SATAKE Corporation Oct 19
Healios K.K. NK Cells Demonstrate Anti-Tumor Effect in Lung Cancer Patient-Derived Cancer Organoids Oct 12
Healios K.K. to Report Q3, 2022 Results on Nov 14, 2022 Oct 09
Consensus forecasts updated Aug 17
First half 2022 earnings released: JP¥59.11 loss per share (vs JP¥36.60 loss in 1H 2021) Aug 12
Healios K.K. to Report Q2, 2022 Results on Aug 10, 2022 May 30
Healios K.K. Reports Top-Line Results from Treasure Study for Ischemic Stroke May 21
First quarter 2022 earnings released: JP¥26.47 loss per share (vs JP¥19.92 loss in 1Q 2021) May 11
Price target decreased to JP¥2,760 Apr 27
Less than half of directors are independent Apr 27
Healios K.K. to Report Q1, 2022 Results on May 16, 2022 Apr 09
Price target decreased to JP¥2,760 Apr 07
Healios K.K. Announces Completion of 365 Days Post-Administration Follow Up for TREASURE Study for Patients with Ischemic Stroke Apr 05
Healios K.K. Provides Progress Update in Relation to Application for Approval for HLCM051 for ARDS Apr 04
Full year 2021 earnings released: JP¥93.36 loss per share (vs JP¥107 loss in FY 2020) Apr 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 17
Healios K.K., Annual General Meeting, Mar 25, 2022 Feb 16
Healios K.K. Announces Announcement of Change in Management Jan 31
Third quarter 2021 earnings released: JP¥34.78 loss per share (vs JP¥29.02 loss in 3Q 2020) Nov 15
HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study Aug 08
First quarter 2021 earnings released: JP¥19.92 loss per share (vs JP¥29.02 loss in 1Q 2020) May 17
Healios K.K. to Report Q1, 2021 Results on May 14, 2021 Feb 28
Athersys, Inc. Announces Cooperation Agreement With HEALIOS K.K Feb 17
New 90-day low: JP¥1,562 Feb 15
Healios K.K. Announces Basic Business Agreement with Spline Corporation Regarding Sales of Pharmaceuticals Feb 06
New 90-day low: JP¥1,724 Jan 15
HEALIOS K.K. Conducts Two Clinical Trials Using Stem Cell Product Hlcm051*1 Jan 04
Healios K.K. to Report Fiscal Year 2020 Results on Jan 12, 2021 Dec 10
Healios K.K. to Report Q3, 2020 Results on Nov 13, 2020 Sep 03
Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: 4593 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: 4593 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi Healios K.K Piyasaya Karşı Temettü Getirisi
4593 temettü verimi piyasa ile karşılaştırıldığında nasıldır? Segment Temettü Verimi Şirket (4593) n/a Pazarın Alt %25'i (JP) 1.8% Pazarın En İyi %25'i (JP) 3.8% Sektör Ortalaması (Biotechs) 1.0% Analist tahmini (4593) (3 yıla kadar) 0%
Önemli Temettü: 4593 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 4593 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: 4593 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranı nı hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: 4593 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
